Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Strategic Expansion into Immunology Biogen Inc. announced this week a definitive agreement to acquire RayThera Inc., a move designed to bolster the pharmaceutical giant’s growing immunology pipeline. The acquisition, finalized in Cambridge, Massachusetts, grants Biogen full ownership of RayThera’s proprietary research assets, most notably a lead candidate currently prepared for Phase 1 clinical testing. This…